HIGFMAG-52K
MILLIPLEX® Human IGF-I, II Magnetic Bead Panel - Endocrine Assay
The Human IGF Panel, using the Luminex xMAP technology, enables the simultaneous analysis of one or both IGF-I and IGF-II protein biomarkers in human serum, plasma and cell/tissue culture samples.
Sign Into View Organizational & Contract Pricing
All Photos(3)
About This Item
UNSPSC Code:
12161503
eCl@ss:
32161000
NACRES:
NA.84
Recommended Products
Quality Level
species reactivity
human
manufacturer/tradename
Milliplex®
assay range
accuracy: 89%
(IGF-II)
sensitivity: 19 pg/mL
(MinDC+2SD; IGF-I)
sensitivity: 919 pg/mL
(MinDC+2SD; IGF-II)
standard curve range: 41-30,000 pg/mL
(IGF-I)
standard curve range: 892-650,000 pg/mL
(IGF-II)
inter-assay cv: <15%
intra-assay cv: <10%
(IGF-I)
inter-assay cv: <15%
intra-assay cv: <10%
(IGF-II)
technique(s)
multiplexing: suitable
UniProt accession no.
detection method
fluorometric (Luminex xMAP)
shipped in
wet ice
Gene Information
human ... IGF1(3479)
General description
Insulin-like Growth Factors I and II are polypeptide, endocrine hormones similar in molecular structure to insulin. Both IGF-I and IGF-II are produced primarily by the liver and their bio-availabilities are regulated by the IGF binding proteins (IGFBPs).
MILLIPLEX® Human IGF-I, II Panel is a 2-plex kit to be used for the quantitative determination of IGF-I and/or IGF-II in human serum, plasma, tissue/cell extracts, or culture media samples. Reagents are included for the extraction of serum and plasma samples resulting in a 1:60 final dilution. This kit uses a 96-well format, contains a lyophilized standard cocktail, two internal assay quality controls and can measure up to 38 samples in duplicate.
The Luminex® xMAP® platform uses a magnetic bead immunoassay format for ideal speed and sensitivity to quantitate multiple analytes simultaneously, dramatically improving productivity while conserving valuable sample volume.
Panel Type: Endocrine
MILLIPLEX® Human IGF-I, II Panel is a 2-plex kit to be used for the quantitative determination of IGF-I and/or IGF-II in human serum, plasma, tissue/cell extracts, or culture media samples. Reagents are included for the extraction of serum and plasma samples resulting in a 1:60 final dilution. This kit uses a 96-well format, contains a lyophilized standard cocktail, two internal assay quality controls and can measure up to 38 samples in duplicate.
The Luminex® xMAP® platform uses a magnetic bead immunoassay format for ideal speed and sensitivity to quantitate multiple analytes simultaneously, dramatically improving productivity while conserving valuable sample volume.
Panel Type: Endocrine
Specificity
Cross Reactivty
There was no or negligible cross-reactivity between the antibodies for an analyte and any of the other analytes in this panel.
There was no or negligible cross-reactivity between the antibodies for an analyte and any of the other analytes in this panel.
Cross-reactivity between the antibodies and any of the other analytes in this panel is non-detectable or negligible.
Application
- Analytes: IGF-I, IGF-II
- Recommended Sample Type: Human serum, plasma, cell/tissue culture supernatants or lysates
- Recommended Sample Dilution: Use 25 μL per well of the final 1:60 extracted serum or plasma; Cell/tissue culture supernatants or lysates may require a dilution in appropriate control medium.
- NOTE: Sample extraction, using the reagents included in the kit, is required for serum and plasma samples. The final dilution for extracted serum or plasma samples is 1:60.
- Assay Run Time: Overnight (16-20 hours) at 2-8°C
- Research Category: Metabolism
- Research Subcategory: Metabolic Disorders
Features and Benefits
Design your multiplex kit by choosing available analytes within this panel.
Packaging
96 well plate
Everything you need in a single kit.
Storage and Stability
Recommended storage for kit components is 2 - 8°C.
Other Notes
Please contact Technical Service for linearity of dilution.
Standard curve range: Refer to analysis sheet for exact standard concentracions.
Legal Information
Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Signal Word
Danger
Hazard Statements
Precautionary Statements
Hazard Classifications
Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Irrit. 2 - Flam. Liq. 2 - Met. Corr. 1 - Skin Sens. 1
Storage Class Code
3 - Flammable liquids
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Josep M Mercader et al.
Diabetes, 66(11), 2903-2914 (2017-08-26)
Type 2 diabetes (T2D) affects more than 415 million people worldwide, and its costs to the health care system continue to rise. To identify common or rare genetic variation with potential therapeutic implications for T2D, we analyzed and replicated genome-wide
Amanda L Ford et al.
Journal of the Academy of Nutrition and Dietetics, 120(4), 500-516 (2020-03-23)
Higher protein intakes may help reduce sarcopenia and facilitate recovery from illness and injury in older adults. However, high-protein diets (HPDs) including animal-sourced foods may negatively perturb the microbiota, and provision of probiotics and prebiotics may mitigate these effects. The
Kenneth Maleta et al.
The American journal of clinical nutrition, 113(2), 380-390 (2021-01-01)
Insulin-like growth factor I (IGF-I) is the most important hormonal promoter of linear growth in infants and young children. The objectives of this study were to compare plasma IGF-I concentration in a low- compared with a high-income country and characterize
Yili Zhang et al.
Journal of inflammation research, 15, 533-543 (2022-02-01)
To investigate the differences of several serum markers among population with different bone mass and to explore the utility of new potential biomarker for the diagnosing and screening for postmenopausal osteoporosis (PMOP). A total of 1055 postmenopausal women were screened
Effects of maternal obstructive sleep apnoea on fetal growth: a prospective cohort study.
Fung, AM; Wilson, DL; Lappas, M; Howard, M; Barnes, M; O'Donoghue, F; Tong, S; Esdale et al.
Testing null
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service